Bifogade filer
Xintela 2024 Q1 EN
Kurs
+11,48%
Likviditet
0,18 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-28 | 07:00 | Bokslutskommuniké 2024 |
| 2024-11-22 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-10 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-15 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2023-05-12 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-28 | - | Extra Bolagsstämma 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-09 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2022-05-06 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-07-05 | - | Extra Bolagsstämma 2021 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-10 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-10 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2020-06-09 | - | Årsstämma |
| 2020-05-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-29 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-28 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2019-05-27 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-28 | - | Kvartalsrapport 2018-Q3 |
| 2018-09-21 | - | Extra Bolagsstämma 2018 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-05-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | X-dag ordinarie utdelning XINT 0.00 SEK |
| 2016-05-30 | - | Årsstämma |
| 2016-04-26 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
First quarter 2024 for the group
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 11,372 (loss: 15,843).
Loss per share was SEK 0.02 (loss: 0.05).
First quarter 2024 for the parent company
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 9,688 (loss: 10,403).
Loss per share was SEK 0.02 (loss: 0.03).
At March 31, 2024, the equity/assets ratio was 52 % (45).
Significant events in the first quarter of 2024
Xintela appoints Lucienne Vonk as Chief Scientific Officer. (February 19, 2024)
Significant events after the end of the period
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses. (May 23, 2024)
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.
Contacts
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).